Abstract
Polycystic ovary syndrome (PCOS) is one of common female endocrine metabolic disorders, characterized by oligo-ovulation and/or anovulation (OA), clinical and/or biochemical hyperandrogenism (HA) and polycystic ovaries (PCO). The clinical manifestations of PCOS are highly complex and heterogeneous. Aside from menstrual and reproductive dysfunctions, PCOS is often associated with long-term health risks, such as obesity, insulin resistance (IR), dyslipidaemia, increased oxidative stress (OS), subclinical chronic inflammation, elevated risks of metabolic syndrome, type 2 diabetes, and future cardiovascular diseases. HA plays an important role in the pathogenesis of PCOS. Increased OS is not only an important factor leading to atherosclerosis and cardiovascular diseases, but also potentially related to the occurrence and progress of PCOS. Recent studies have shown that there was a strong association between HA and increased OS in PCOS. In this article, we focus on the sources of OS molecules and the antioxidant defense mechanisms, the OS status in PCOS and its relationship with HA, the interaction and its impossible mechanisms between HA and OS, and the current status and future prospects of OS prevention and treatment in patients with PCOS. Key words: Polycystic ovary syndrome; Hyperandrogenism; Oxidative stress; Female
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.